Recent advances in diagnosis and management of chronic bronchitis and emphysema

Current Opinion in Pulmonary Medicine

Volumn 8, Issue 2, 2002, Pages 126-136

  Chitkara, Rajinder K ^a   Sarinas, Priscilla S A ^a  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; ANTIOXIDANT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CELL ADHESION MOLECULE BLOCKING AGENT; CHEMOKINE; CHEMOKINE INHIBITOR; CIPROFLOXACIN; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; HELIOX; I KAPPA B; INTERLEUKIN 10; IPRATROPIUM BROMIDE; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; METHYLXANTHINE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PROSTANOID INHIBITOR; SALBUTAMOL; SALMETEROL; SYNAPTOPHYSIN; THEOPHYLLINE; TIOTROPIUM BROMIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AIRWAY DYNAMICS; ARTIFICIAL VENTILATION; BIOCHEMISTRY; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE EXACERBATION; EARLY DIAGNOSIS; EMPHYSEMA; HEALTH ECONOMICS; HISTOPATHOLOGY; HUMAN; INFECTION; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; PREVALENCE; RADIODIAGNOSIS; RESOURCE ALLOCATION; RESPIRATORY TRACT DISEASE; REVIEW; SIDE EFFECT; SURGICAL TECHNIQUE; UNITED STATES;

EID: 0036171438     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200203000-00008     Document Type: Review

References (102)

1. End-stage chronic obstructive pulmonary disease: The cigarette is burned out but inflammation rages on
2. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary lung disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary
3. COPD: Early detection and intervention
4. Office spirometry for lung health assessment in adults: A consensus statement from the National Lung Health Education Program
5. 6 is an acceptable surrogate for FVC in the spirometric diagnosis of airway obstruction and restriction
6. Controversies in the use of spirometry for early recognition and diagnosis of chronic obstructive pulmonary disease in cigarette smokers
7. Emerging concepts in the evaluation of ventilatory limitation during exercise: The exercise tidal flow-volume loop
8. Mechanisms and measures of exercise intolerance in chronic obstructive pulmonary disease
9. Expiratory flow limitation
10. Relation between chronic dyspnea and expiratory flow limitation in patients with chronic obstructive pulmonary disease
11. Advances in radiologic assessment of chronic obstructive pulmonary disease
12. Physiological and radiologic characterization of patients diagnosed with chronic obstructive pulmonary disease in primary care
13. Assessment of airway neutrophils by sputum color: Correlation with airway inflammation
14. Relation between airway inflammation and the frequency of exacerbations in patients with smoking related COPD
15. Sputum and plasma endothelin-1 levels in acute exacerbations of chronic obstructive pulmonary disease
16. Cellular and structural bases of chronic obstructive pulmonary disease
17. Chronic obstructive pulmonary disease
18. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study
19. A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report
20. Smoking cessation: Techniques and benefits
21. Smoking cessation in patients with chronic obstructive pulmonary disease: A double-blind, placebo-controlled, randomized trial
22. Smoking cessation
23. New developments in smoking cessation
24. Bupropion for smoking cessation: Predictors of successful outcome
25. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation: A randomized, controlled trial
26. Effects of supplemental oxygen during activity in patients with advanced COPD without severe resting hypoxemia
27. Incidence of nocturnal desaturation while breathing oxygen in COPD patients undergoing long-term oxygen therapy
28. A review of long-term oxygen therapy for chronic obstructive pulmonary disease
29. A hazard of home oxygen therapy
30. Skeletal muscle dysfunction in chronic obstructive pulmonary disease and chronic heart failure: Underlying mechanisms and therapy perspectives
31. Skeletal muscle strength and endurance in patients with mild COPD and the effects of weight training
32. Comparison of effects of supervised versus self-monitored training programs in patients with chronic obstructive pulmonary disease
33. Long-term effects of outpatient rehabilitation of COPD: A randomized trial
34. The effectiveness of outpatient pulmonary rehabilitation in chronic lung disease: A randomized controlled trial
35. Is it really useful to repeat outpatient pulmonary rehabilitation programs in patients with chronic airway obstruction? a 2-year controlled study
36. Characterization of non-response to high caloric oral nutritional therapy in depleted patients with chronic obstructive pulmonary disease
37. Chronic obstructive pulmonary disease and intake of catechins, flavonols, and flavones: The MORGEN Study
38. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease
39. Antimuscarinic treatment for lung diseases from research to clinical practice
40. Anticholinergic therapy for airway diseases
41. Update on pharmacologic therapy for chronic obstructive pulmonary disease
42. The future for tiotropium
43. Anticholinergic bronchodilators in combination
44. The spirometric efficacy of once daily dosing with tiotropium in stable COPD: A 13-week multi-center trial
45. Long-acting bronchodilation with once daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease
46. A randomized controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease
47. Tiotropium bromide
48. Does inhaled albuterol improve diaphragmatic contractility in patients with chronic obstructive pulmonary disease?
49. Regular versus as-needed short-acting inhaled beta-agonist therapy for chronic obstructive pulmonary disease
50. Alternative mechanisms for long-acting β-2 adrenergic agonists in COPD
51. Use of a long-acting inhaled beta2 adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease
52. Long-acting beta2 agonists in the management of stable chronic obstructive pulmonary disease
53. Economic burden of chronic obstructive pulmonary disease: Impact of new treatment options
54. Salmeterol plus theophylline combination therapy in the treatment of COPD
55. Inhaled salmeterol/fluticasone propionate combination: A pharmacoeconomic review of its use in the management of asthma
56. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease
57. Role of corticosteroids in acute exacerbations of chronic obstructive pulmonary disease
58. Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids
59. Withdrawal of chronic systemic corticosteroids in patients with COPD: A randomized trial
60. Corticosteroids in chronic obstructive pulmonary disease: Clinical benefits and risks
61. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease
62. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking
63. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease
64. Relation of FEV(1) to clinical outcomes during exacerbations of chronic obstructive pulmonary disease
65. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease
66. Management of acute exacerbations of chronic obstructive pulmonary disease: A summary and appraisal of published evidence
67. Bacteria, antibiotics and COPD
68. Acute exacerbation of COPD: Factors associated with poor treatment outcome
69. Management of acute exacerbations of COPD: A summary and appraisal of published evidence
70. Antibiotic therapy in acute exacerbations of chronic bronchitis
71. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: Systematic review
72. Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease
73. The Bronchitis Randomized On NAC Cost-Utility Study (BRONCUS): Hypothesis and design
74. Non-invasive positive pressure ventilation for exacerbation of chronic obstructive pulmonary patients in the emergency department
75. Noninvasive ventilation and obstructive lung disease
76. Effects of biphasic positive airway pressure in patients with chronic obstructive pulmonary disease
77. Beneficial effects of helium: Oxygen versus air: Oxygen non-invasive pressure support in patients with decompensated chronic obstructive pulmonary disease
78. Nasal proportional assist ventilation unloads the inspiratory muscles of stable patients with hypercapnia due to COPD
79. Proportional assist ventilation may improve exercise performance in severe chronic obstructive pulmonary disease
80. Physiologic effects of negative pressure ventilation in acute exacerbation of chronic obstructive pulmonary disease
81. Noninvasive ventilation in COPD patients with chronic respiratory failure: Pro
82. Noninvasive ventilation in COPD patients with chronic respiratory failure: Con
83. Randomized trial of the use of heliox as a driving gas for updraft nebulization of bronchodilators in the emergent treatment of acute exacerbations of chronic obstructive pulmonary disease
84. Noninvasive ventilation with helium-oxygen in acute exacerbations of chronic obstructive pulmonary disease
85. Effects of helium-oxygen on intrinsic positive end-expiratory pressure in intubated and mechanically ventilated patients with severe chronic obstructive pulmonary disease
86. Effects of lung volume reduction surgery for emphysema on diaphragm dimensions and configuration
87. Patients at high risk of death after lung volume-reduction surgery
88. Bronchoscopic volume reduction: A safe and effective alternative to surgical therapy for emphysema
89. Worldwide thoracic organ transplantation: A report from UNOS/ISHLT international registry for thoracic organ transplantation
90. Novel approaches and targets for treatment of chronic obstructive pulmonary disease
91. Novel therapy for COPD
92. New approaches to the management of COPD
93. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: A randomized, dose-ranging study
94. New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease
95. Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies
96. Ariflo (SB 207499), a second-generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: From concept to clinic
97. Does sildenafil also improve breathing?
98. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension